ClinicalTrials.gg
RecruitingNCT04333108Updated May 6, 2023

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

A Phase 3 interventional study of Masitinib and Placebo in Indolent Systemic Mastocytosis, sponsored by AB Science. Recruiting at 17 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Mastocytosis, Systemic with a site in France — 6 open to participants now, 8 under way, 2 of them phase 3. Mastocytosis, Systemic · France.

Planned enrollment
6th of 15
140 · median 135
Started
2020
with 1 other
Phase 3
3 of 18
1 open now
Registered
11th of 18
by date
Lead sponsor
2 of 18
AB Science

Among the 18 studies in Mastocytosis, Systemic with a site in France, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 3, and was the 11th registered.

Mastocytosis, Systemic

56 studies on the registry are indexed under Mastocytosis, Systemic; 16 are open to participants now.

Browse Mastocytosis, Systemic studies →

Open to participants now

6 of the 18 studies in Mastocytosis, Systemic with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 14 Mastocytosis, Systemic studies recruiting now, 12 (86%) set no upper age limit and 2 (14%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Mastocytosis, Systemic with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients suffering from smouldering or indolent systemic mastocytosis with severe symptoms of mast cell mediator release, unresponsive to optimal symptomatic treatment.

Read the detailed description

Masitinib is a selective tyrosine kinase inhibitor that modulates mast cell activity via inhibition of c-Kit, Lyn and Fyn kinase signaling pathways. This is a multicenter, randomized, double-blind, placebo-controlled, 2-parallel-group, trial comparing oral masitinib versus placebo in the treatment of patients suffering from smouldering or indolent systemic mastocytosis with severe symptoms of mast cell mediator release (also referred to as handicaps), unresponsive to optimal symptomatic treatment. The treatment period is 24 weeks. Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.

03

Conditions studied

  • Indolent Systemic Mastocytosis

Keywords

  • Mastocytosis with handicap
  • Mastocytosis
  • Mast cell
  • Mast cell infiltration
  • Skin
  • Bone marrow
  • Pruritus
  • Flushes
  • c-kit
  • c-kit mutation
  • Wild Type
  • Mutation Asp-816-Val(D816V)
  • Indolent systemic mastocytosis
  • smoldering systemic mastocytosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with one of the following documented mastocytosis subtypes (variants): Smouldering Systemic Mastocytosis, Indolent Systemic Mastocytosis
  2. An excess of mast cells or a presence of abnormal mast cells in at least two organs (among skin, bone-marrow and GI Tract).
  3. Patient with documented systemic mastocytosis and evaluable disease based upon histological criteria
  4. Patient with documented treatment failure of his/her symptom(s) (within the past 2 years) with at least two of the symptomatic treatments used at optimized dose: Anti H1, Anti H2, Proton pump inhibitor, Antidepressants, Cromoglycate Sodium, Antileukotriene.
  5. Patient with severe symptoms of mastocytosis over the 14-day run-in period including at least one among pruritus, flushes, and depression: pruritus score ≥ 9, number of flushes per week ≥ 8, Hamilton rating scale for depression (HAMD-17) score ≥ 19.

Exclusion criteria

Exclusion Criteria:

  1. Patient with one of the following mastocytosis: Cutaneous Mastocytosis, Systemic Mastocytosis with an Associated clonal Hematologic Non Mast cell lineage Disease (SM-AHNMD), Mast cell leukemia (MCL), Aggressive systemic mastocytosis (ASM)
  2. Previous treatment with any Tyrosine Kinase Inhibitor
  3. Treatment with any agent within 8 weeks prior to screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Masitinib & BSC

    Experimental Arm: Masitinib (titration to 6.0 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC). Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.

    Drug: Masitinib · Other: Best Supportive Care

  • Placebo comparator
    Placebo & BSC

    Placebo Comparator: Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)

    Other: Placebo · Other: Best Supportive Care

Interventions

  • Masitinib 6 mg/kg/day

    Also known as: AB1010

  • OtherPlacebo

    Matching placebo

  • OtherBest Supportive Care

    Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglycate, antidepressants, leukotriene antagonists and corticosteroids.

06

What researchers measure

Primary outcomes

  1. Cumulative response (3R75%)

    Cumulative response in at least one of three severe baseline symptoms of mast cell mediator release (pruritus, flushes, or depression). Response was defined as a 75% improvement from baseline for any of these three symptoms. Cumulative response was defined as the number of actual responses between weeks 8 and 24, divided by the total number of possible responses over the same treatment period (ie, with five scheduled visits, each patient had a maximum of five to 15 possible responses depending on the number of severe baseline symptoms).

    Time frame: 24 weeks

Secondary outcomes

  1. Cumulative response (4R75%)

    Cumulative response in at least one of four severe baseline symptoms of mast cell mediator release (pruritus, flushes, depression, or asthenia). Response is defined as a 75% improvement from baseline for any of these four symptoms. Cumulative response was defined as the number of actual responses between weeks 8 and 24, divided by the total number of possible responses over the same treatment period (ie, with five scheduled visits, each patient had a maximum of five to 20 possible responses depending on the number of severe baseline symptoms).

    Time frame: 24 weeks

  2. Cumulative response (2R75%)

    Cumulative response in at least one of two severe baseline symptoms of mast cell mediator release (pruritus or flushes). Response is defined as a 75% improvement from baseline for either of these two symptoms. Cumulative response is defined as the number of actual responses between weeks 8 and 24, divided by the total number of possible responses over the same treatment period (ie, with five scheduled visits, each patient had a maximum of five to 10 possible responses depending on the number of severe baseline symptoms).

    Time frame: 24 weeks

  3. Cumulative response

    Cumulative response on each of the individual handicaps. Response is defined as a 75% improvement from baseline for either of these two symptoms. Cumulative response is defined as the number of actual responses between weeks 8 and 24, divided by the total number of possible responses over the same treatment period.

    Time frame: 24 weeks

07

Study locations

16 of 17 sites recruiting
  • Centre Hospitalier Universitaire d'Amiens
    Amiens, France
    Recruiting
  • Hospital Jean-Minjoz
    Besançon, France
    Recruiting
  • Grenoble University Hospital
    Grenoble, France
    Recruiting
  • Hospital Claude Huriez
    Lille, France
    Recruiting
  • Marseille University Hospital Timone
    Marseille, France
    Recruiting
  • Centre de référence de Mastocytose (CEREMAST)
    Paris, France
    Recruiting
  • Poitiers University Hospital
    Poitiers, France
    Recruiting
  • Centre Hospitalier Universitaire
    Toulouse, France
    Recruiting
  • University Hospital Charité
    Berlin, Germany
    Not yet recruiting
  • Erasmus University Medical Center
    Rotterdam, Netherlands
    Recruiting
  • Medical University of Gdańsk
    Gdańsk, Poland
    Recruiting
  • The University Hospital in Krakow (Szpital Uniwersytecki w Krakowie)
    Kraków, Poland
    Recruiting
  • University Hospital in Bucharest (Spitalul Universitar de Urgență București)
    Bucharest, Romania
    Recruiting
  • Almazov National Medical Research Centre
    Saint Petersburg, Russian Federation
    Recruiting
  • Dnipropetrovsk Clinical Association of Emergency Medical Care of Dnipropetrovsk Regional
    Dnipropetrovs'k, Ukraine
    Recruiting
  • Private Enterprise Private Manufacturing Company Acinus
    Poltava, Ukraine
    Recruiting
  • Guy's and St Thomas' NHS Foundation Trust
    London, United Kingdom
    Recruiting
08

References and documents

Publications

  • Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, Grandpeix-Guyodo C, Dubreuil P, Palmerini F, Mansfield CD, Gineste P, Moussy A, Hermine O, Lortholary O. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol. 2010 Dec;85(12):921-5. doi: 10.1002/ajh.21894. PubMed 21108325 ↗
  • Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Georgin Lavialle S, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet. 2017 Feb 11;389(10069):612-620. doi: 10.1016/S0140-6736(16)31403-9. Epub 2017 Jan 7. PubMed 28069279 ↗
  • Latham BD, Oskin DS, Crouch RD, Vergne MJ, Jackson KD. Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib. Chem Res Toxicol. 2022 Sep 19;35(9):1467-1481. doi: 10.1021/acs.chemrestox.2c00057. Epub 2022 Sep 1. PubMed 36048877 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2020 (actual). Primary completion is estimated for Dec 2024, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2020
First posted
Apr 3, 2020
StartActual
Jul 1, 2020
Primary completionEst.
Dec 2024
CompletionEst.
Jun 2025
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04333108
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Apr 3, 2020
Start date
Jul 1, 2020
Primary completion
Dec 2024 (estimated)
Completion
Jun 2025 (estimated)
Last update
May 6, 2023

Study contacts

Clinical Study Coordinator
Contact
clinical@ab-science.com
+33(0)147200014
Cristina Bulai Livideanu, MD, MSc
principal investigator · Centre Hospitalier Universitaire, Service de Dermatologie, Toulouse -France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion